Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 29;77(7):2038-2039.
doi: 10.1093/jac/dkac104.

Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19

Jean Jacques Parienti  1   2 , Harm Jan de Grooth  3   4
Affiliations

Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19

Jean Jacques Parienti et al. J Antimicrob Chemother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Clinical benefit (y-axis) by relative SARS-CoV-2 viral load reduction (x-axis) in outpatient COVID-19 trials. Point size is proportional to inverse of the effect size variance. The vertical red dashed line denotes the surrogate threshold effect (STE): the minimum increase in viral load reduction necessary to predict a significant reduction in hospitalization or death. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
See this image and copyright information in PMC

References

    1. Forrest JI, Rayner CR, Park JJHet al. . Early treatment of COVID-19 disease: A missed opportunity. Infect Dis Ther 2020; 9: 715–20. - PMC - PubMed
    1. Liu Y, Yan L-M, Wan Let al. . Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020; 20: 656–7. - PMC - PubMed
    1. Néant N, Lingas G, Le Hingrat Qet al. . Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci U S A 2021; 118: e2017962118. - PMC - PubMed
    1. FDA . COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. U.S. Food and Drug Administration. 2021; published online 23 June. https://www.fda.gov/regulatory-information/search-fda-guidance-documents....
    1. de Grooth H-J, Parienti J-J, Oudemans-van Straaten HM. Should we rely on trials with disease- rather than patient-oriented endpoints? Intensive Care Med 2018; 44: 464–6. - PMC - PubMed

Publication types